RE:Is this........ I think so.
MIR has done everything necessary to make the granting of EUA low risk for the FDA, particularly given their existing portfolio of FDA approved tests.
We were already expecting EUA this month based on the timelines of other submissions and approvals. This recent independent study further validates this.
EUA will take MIR to new highs. Next will (probably) be news on US manufacting. It is highly likely this is already in progress awaiting EUA... as the Webb website says, RevealCovid-19 will be manufactured in the US and, due to its simple design, can be easily and inexpensively mass produced.
With these announcements, MIR could flirt with $1 Billion market cap because the market realizes it's product is not only accurate and user friendly, but is based on a patented (until 2032) technology that makes it extremely fast (1-3 mins) relative to lateral flow tests.
As I said before, the market is focused on antigen and PCR given the state of emergency, however the overall market for these tests is likely very much smaller than antibody given that antibody tests could, with the rollout of vaccines, be used on the majority of a population multiple times for many years.